AlbuRx® 5, AlbuRx® 25
Albumin (Human) 5% Solution and 25% Solution
AlbuRx
® 5 is indicated for use in patients with shock, burns, pancreatitis and peritonitis, postoperative albumin loss, and hypoproteinemia with oncotic deficit.
AlbuRx
® 25 is indicated for use in patients with volume deficit/oncotic deficit. AlbuRx
® 25 is usually appropriate in the following acute circumstances: shock and burns. AlbuRx
® 25 may be appropriate in the following acute circumstances: adult respiratory distress syndrome (ARDS), cardiopulmonary bypass, pre- and postoperative hypoproteinemia, third space problems of infectious origin, acute liver failure, acute nephrosis, ascites, red cell resuspension media, renal dialysis, and hemolytic disease of the newborn.
While AlbuRx® 5 or 25 may be needed to treat acute complications
of chronic hypoproteinemia, they are not indicated for treatment of the
chronic condition itself.
AlbuRx® is a solution containing the most abundant protein in
human plasma, albumin, which is produced by the liver. Scientists first isolated
albumin from plasma during World War II while researching a substitute for whole
blood in the treatment of military casualties.
AlbuRx® is used to expand the volume of fluid in the vascular
compartment and to replace naturally occurring albumin in patients whose bodies
do not have enough of the protein in the blood stream (hypoproteinemia).
AlbuRx® is available in 5% and 25% solutions and is manufactured
from U.S.-donor plasma in our state-of-the-art manufacturing facility in Bern,
Switzerland.
AlbuRx® 5
Albumin (Human) 5% Solution
NDC Number |
Product Description |
| 44206-310-25 |
250 mL |
| 44206-310-50 |
500 mL |
AlbuRx® 25
Albumin (Human) 25% Solution
|
NDC Number |
Product Description |
| 44206-251-05 |
50 mL |
| 44206-251-10 |
100 mL |
Important Safety Information
The use of AlbuRx® 5 and 25 is contraindicated in patients with a
history of an incompatibility reaction to albumin (human). In addition,
AlbuRx® 5 may be contraindicated in patients with cardiac failure or
severe anemia because of the risk of acute circulatory overload.
Though very rare, non-septic incompatibility reactions including nausea,
chills, fever, urticaria, headache, and hypotension following the administration
of albumin-containing preparations have occasionally been observed.
AlbuRx® is derived from human plasma. As with all plasma-derived
products, the risk of transmission of infectious agents, including viruses and,
theoretically, the Creutzfeldt-Jakob (CJD) disease agent, cannot be completely
eliminated.
Please see the
full prescribing information for AlbuRX® 5.
Please see the
full prescribing for AlbuRx® 25.
View universal billing codes for AlbuRx® 5 and AlbuRx® 25
CUSTOMER SUPPORT 1-800-683-1288 or
Customer Services
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
Frequently Asked Questions for AlbuRx® 5, AlbuRx® 25
Last Updated: 07 April 2009